SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–July 20, 2020–
Circle Pharma, Inc. has appointed Rajinder Singh, PhD as its Chief Science Officer. Dr. Singh will oversee Circle’s scientific work to develop macrocycle therapeutics in opposition to intractable most cancers targets.
Dr. Singh has 25 years of expertise in drug discovery and growth, spanning small molecules, peptides and peptoids. He most just lately served as Senior Vice President of Research and Pharmaceutics at ChemoCentryx and earlier in his profession had senior roles at Rigel, Inc. and Chiron. He was awarded a doctorate in Organic chemistry from the University of Oxford the place he studied below Prof. Sir Jack Baldwin, and subsequently undertook a postdoctoral analysis fellowship at Eli Lilly & Company.
“We are delighted to have Raj join the Circle team.” mentioned David J. Earp, J.D., Ph.D., Circle’s President and CEO. “Raj brings deep experience in therapeutics research and development across chemistry, biology, pharmacology and pharmaceutics. He has built and led teams that have advanced multiple programs from discovery through pre-clinical optimization, and from Phase 1 to pivotal clinical studies. Raj is one of the inventors of Syk kinase inhibitor Tavalisse (fostamatinib) and most recently has supported the NDA submission for C5aR inhibitor avacopan. I am very much looking forward to working with Raj to bring Circle’s therapies to patients.”
“We would also like to express our deep appreciation to Dr. David Spellmeyer, who has served as Circle’s interim CSO since October 2017. With David’s scientific guidance and leadership, we have significantly advanced our macrocycle drug discovery platform and our cyclin programs. David will continue as an advisor to Circle, focusing on informatics and computational chemistry.”
About Circle Pharma, Inc.
Circle is growing a brand new paradigm for macrocycle drug discovery primarily based on rational design and artificial chemistry. Circle’s know-how facilitates the design and synthesis of intrinsically cell-permeable macrocycles that may tackle each intra- and extra-cellular therapeutic targets, and will be delivered by oral administration. Circle’s macrocycle growth platform is relevant throughout a variety of significant illnesses; the corporate is initially focusing its growth efforts on intracellular protein-protein interactions which are key drivers in most cancers. Its lead applications goal cyclins A and E, that are a part of the regulatory equipment that controls the development of cells by means of the cell development and division cycle. Inhibition of Cyclin A has been proven to be synthetically deadly in cancers pushed by mutations within the Rb pathway. Cyclin E upregulation is related to resistance to medicine that concentrate on cdk4/6 exercise and can be discovered throughout a number of most cancers sorts.
More data: www.circlepharma.com